Synthetic cannabinoids: Spread, addiction biology & current perspective of personal health hazard;Synthetische Cannabinoide: Verbreitung, Suchtbiologie & aktuelle Perspektive der persönlichen Gesundheitsgefährdung

Fortschritte der Neurologie Psychiatrie

Volumn 83, Issue 4, 2015, Pages 221-231

  Bonnet, U ^a   Mahler, H ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Kriminalwissenschaftliches und technisches Institut Landeskriminalamt Nordrhein Westfalen   (Germany)

Author keywords

cannabis; cannabis harms; dependence potential; ranking; synthetic cannabinoids; toxicity

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CANNABINOID; CATHINONE; PSYCHOTROPIC AGENT; SYNTHETIC CANNABINOID; UNCLASSIFIED DRUG; ALKALOID; CANNABINOID RECEPTOR; DESIGNER DRUG; STREET DRUG;

ADDICTION; ALGORITHM; ARTICLE; CANNABIS USE; CONFUSION; HALLUCINATION; HEALTH HAZARD; HEART INFARCTION; HEDGEHOG; LAW; PANIC; PARANOIA; TACHYCARDIA; COMPLICATION; DRUG EFFECTS; EUROPE; HUMAN; MARIJUANA ABUSE; META ANALYSIS; PATHOPHYSIOLOGY; PSYCHOLOGY;

ALKALOIDS; CANNABINOIDS; DESIGNER DRUGS; EUROPE; HUMANS; MARIJUANA ABUSE; RECEPTORS, CANNABINOID; STREET DRUGS;

EID: 84928467834     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0034-1399307     Document Type: Article

References (107)

1. UNDOC World Drug Report 2013 - new psychoactive substances (NPS). Im Internet: http://www.unodc.org/wdr/en/nps.html Stand: 08.02.2015
2. UNDOC World Drug Report 2014 - amphetamine-type substances (ATS) and new psychoactive substances (NPS). Im Internet: http://www.unodc.org/documents/wdr2014/ATS-NPS-2014-web.pdf Stand: 08.02.2015
3. Schneir A. B., Cullen J., Ly B. T. Spice girls: synthetic cannabinoid intoxication. J Emerg Med: 2011; 40 296 299
4. Harris C. R., Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med: 2013; 44 360 366
5. Helander A., Bäckberg M., Hultén P. et al. Detection of new psychoactive substance use among emergency room patients: Results from the Swedish STRIDA project. Forensic Sci Int: 2014; 243 23 29
6. Seely K. A., Patton A. L., Moran C. L. et al. Forensic investigation of K2, Spice, and bath salt commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int: 2013; 233 416 422
7. Auwärter V., Dresen S., Weinmann W. et al. Spice and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom: 2009; 44 832 837
8. Atwood B. K., Huffman J., Straiker A. et al. JWH018, a common constituent of Spice herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol: 2010; 160 585 593
9. Spaderna M., Addy P. H., D'Souza D. C. Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl): 2013; 228 525 540
10. Huffman J. W., Zengin G., Wu M. J. et al. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem: 2005; 13 89 112
11. Europäische Beobachtungsstelle für Drogen und Drogensucht: Drogenangebot in Europa (EMCDDA) Perspectives on drugs. Synthetic cannabinoids in Europe, update 16.5. 2014. Im Internet: http://www.emcdda.europa.eu/attachements.cfm/att-212361-EN-EMCDDA-POD-2013-Synthetic%20cannabinoids.pdf Stand: 08.02.2015
12. Uchiyama N., Matsuda S., Kawamura M. et al. The new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivates, ADP-FUBINACA and ADBICA, and five cannabinoids detected with thiophene derivate α-PVT and an opioid agonist AH-7921 identified in illegal products. Forensic Toxicol: 2013; 31 223 230
13. Europäische Beobachtungsstelle für Drogen und Drogensucht: Drogenangebot in Europa (EMCDDA) In: Europäischer Drogenbericht 2013: Trends und Entwicklungen. Luxemburg Amt für Veröffentlichungen der Europäischen Union: 2013; 28 29
14. Europäische Beobachtungsstelle für Drogen und Drogensucht: Drogenangebot in Europa (EMCDDA) Europäischer Drogenbericht 2014: Trends und Entwicklungen. Im Internet: http://www.emcdda.europa.eu/attachements.cfm/att-228272-DE-TDAT14001DEN.pdf Stand: 08.02.2015
15. Gunderson E. W., Haughey H. M., Ait-Daoud N. et al. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus: 2014; 35 184 189
16. Pabst A., Kraus L., Gomes de Matos E. et al. Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. Sucht: 2013; 59 321 331
17. Reid M. J., Baz-Lomba J. A., Ryu Y. et al. Using biomarkers in wastewater to monitor community drug use: a conceptual approach for dealing with new psychoactive substances. Sci Total Environ: 2014; 487 651 658
18. Brents L. K., Prather P. L. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev: 2014; 46 72 85
19. Fadda P., Scherma M., Spano M. S. et al. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport: 2006; 17 1629 1632
20. Maldonado R., Berrendero F., Ozaita A. et al. Neurochemical basis of cannabis addiction. Neuroscience: 2011; 181 1 17
21. Flores Á, Maldonado R., Berrendero F. The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward. Biol Psychiatry: 2014; 75 499 507
22. Fantegrossi W. E., Moran J. H., Radominska-Pandya A. et al. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sci: 2014; 97 45 54
23. Järbe T. U., Gifford R. S. Herbal incense: designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays. Life Sci: 2014; 97 64 71
24. Franklin J. M., Mathew M., Carrasco G. A. Cannabinoid-induced upregulation of serotonin 2A receptors in the hypothalamic paraventricular nucleus and anxiety-like behaviors in rats. Neurosci Lett: 2013; 548 165 169
25. EMCDDA Molekülstrukturen. Im Internet: http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids#panel2
26. Bundesministeriums der Justiz und für Verbraucherschutz Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG). Letzte Änderung am 5.12.2014. http://www.gesetze-im-internet.de/bundesrecht/btmg-1981/gesamt.pdf Stand: 08.02.2015
27. Tomiyama K., Funada M. Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and apoptotic cell death. Toxicol Appl Pharmacol: 2014; 274 17 23
28. Koller V. J., Auwärter V., Grummt T. et al. Investigation of the in vitro toxicological properties of the synthetic cannabimimetic drug CP-47,497-C8. Toxicol Appl Pharmacol: 2014; 277 164 171
29. Dhopeshwarkar A., Mackie K. CB2 cannabinoid receptors as a therapeutic target - What does the future hold? Mol Pharmacol: 2014; 86 430 437
30. Shanks K. G., Behonick G. S., Dahn T. et al. Identification of novel third-generation synthetic cannabinoids in products by ultra-performance liquid chromatography and time-of-flight mass spectrometry. J Anal Toxicol: 2013; 37 517 525
31. Castaneto M. S., Gorelick D. A., Desrosiers N. A. et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend: 2014; 144 12 41
32. Martin B. R., Compton D. R., Thomas B. F. et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav: 1991; 40 471 478
33. Cha H. J., Lee K. W., Song M. J. et al. Dependence Potential of the Synthetic Cannabinoids JWH-073, JWH-081, and JWH-210: In Vivo and In Vitro Approaches. Biomol Ther. (Seoul): 2014; 22 363 369
34. Ginsburg B. C., Schulze D. R., Hruba L. et al. JWH-018 and JWH-073: Δ-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther: 2012; 340 37 45
35. Hruba L., Ginsburg B. C., McMahon L. R. Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ-tetrahydrocannabinol treatment in rhesus monkeys. J Pharmacol Exp Ther: 2012; 342 843 849
36. Hyatt W. S., Fantegrossi W. E. Δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice. Behav Pharmacol: 2014; 25 253 257
37. Gronewold A., Skopp G. A preliminary investigation on the distribution of cannabinoids in man. Forensic Sci Int: 2011; 210 e7 e11
38. Chimalakonda K. C., Seely K. A., Bratton S. M. et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos: 2012; 40 2174 2184
39. Chimalakonda K. C., Bratton S. M., Le V. H. et al. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos: 2011; 39 1967 1976
40. De Brabanter N., Esposito S., Tudela E. et al. In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. Rapid Commun Mass Spectrom: 2013; 27 2115 2126
41. Teske J., Weller J. P., Fieguth A. et al. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci: 2010; 878 2659 2663
42. Gandhi A. S., Zhu M., Pang S. et al. First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J: 2013; 15 1091 1098
43. Krasowski M. D., Ekins S. Using cheminformatics to predict cross reactivity of designer drugs to their currently available immunoassays. J Cheminform: 2014; 6 22
44. Arntson A., Ofsa B., Lancaster D. et al. Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. J Anal Toxicol: 2013; 37 284 290
45. Castaneto M. S., Desrosiers N. A., Ellefsen K. et al. Method validation of the biochip array technology for synthetic cannabinoids detection in urine. Bioanalysis: 2014; 21 2919 2930
46. Smith D. L., Roberts C. Synthetic marijuana use and development of catatonia in a 17-year-old male. Minn Med: 2014; 97 38
47. Buser G. L., Gerona R. R., Horowitz B. Z. et al. Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol (Phila): 2014; 52 664 673
48. Mir A., Obafemi A., Young A. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics: 2011; 128 e1622 e1627
49. Gunderson E. W., Haughey H. M., Ait-Daoud N. et al. Spice and K2 herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict: 2012; 21 320 326
50. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend: 2011; 117 152 157
51. Hermanns-Clausen M., Kneisel S., Szabo B. et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction: 2013; 108 534 544
52. Hopkins C. Y., Gilchrist B. L. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med: 2013; 45 544 546
53. Nacca N., Vatti D., Sullivan R. et al. The synthetic cannabinoid withdrawal syndrome. J Addict Med: 2013; 7 296 298
54. Zimmermann U. S., Winkelmann P. R., Pilhatsch M. et al. Withdrawal phenomena and dependence syndrome after the consumption of spice gold Dtsch Arztebl Int: 2009; 106 464 467
55. Rominger A., Cumming P., Xiong G. et al. Effects of acute detoxification of the herbal blend Spice Gold on dopamine D2/3 receptor availability: a [18F]fallypride PET study. Eur Neuropsychopharmacol: 2013; 23 1606 1610
56. Behonick G., Shanks K. G., Firchau D. J. et al. Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22. J Anal Toxicol: 2014; 38 559 562
57. Schaefer N., Peters B., Bregel D. et al. A fatal case involving several synthetic cannabinoids. Toxichem Krimtech: 2013; 80 (Special Issue) 248 251
58. Ibrahim S., Al-Saffar F., Wannenburg T. A Unique Case of Cardiac Arrest following K2 Abuse. Case Rep Cardiol: 2014; 2014 120607
59. Patton A., Chimalakonda K. C., Moran C. L. et al. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci: 2013; 58 1676 1680
60. Saito T., Namara A., Miura N. et al. A fatal case of MAM-2201 poisoning. Forensic Toxicol: 2013; 31 333 337
61. Kronstrand R., Roman M., Andersson M. et al. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol: 2013; 37 534 541
62. Wikström M., Thelander G., Dahlgren M. et al. An accidental fatal intoxication with methoxetamine. J Anal Toxicol: 2013; 37 43 46
63. Ware M. A., St Arnaud-Trempe E. The abuse potential of the synthetic canabinonid nabilone. Addiction: 2010; 105 494 503
64. Winstock A. R., Barratt M. J. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend: 2013; 131 106 111
65. Winstock A. R., Barratt M. J. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol: 2013; 28 390 393
66. Musshoff F., Madea B., Kernbach-Wighton G. et al. Driving under the influence of synthetic cannabinoids (Spice): a case series. Int J Legal Med: 2014; 128 59 64
67. Bonar E. E., Ashrafioun L., Ilgen M. A. Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates. Drug Alcohol Depend: 2014; 143 268 271
68. Papanti D., Schifano F., Botteon G. et al. Spiceophrenia: a systematic overview of spice-related psychopathological issues and a case report. Hum Psychopharmacol: 2013; 28 379 389
69. Hodcroft C. J., Rossiter M. C., Buch A. N. Cannabis-associated Myocardial Infarction in a Young Man with Normal Coronary Arteries. J Emerg Med: 2014; 47 277 281
70. Bernson-Leung M. E., Leung L. Y., Kumar S. Synthetic cannabis and acute ischemic stroke. J Stroke Cerebrovasc Dis: 2014; 23 1239 1241
71. Hohmann N., Mikus G., Czock D. Wirkungen und Risiken neuartiger psychoaktiver Substanzen. Dtsch Arztebl: 2014; 111 139 147
72. Derungs A., Schwaninger A. E., Mansella G. et al. Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol: 2013; 31 164 171
73. McQuade D., Hudson S., Dargan P. I. et al. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol: 2013; 69 373 376
74. Monte A. A., Bronstein A. C., Cao D. J. et al. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med: 2014; 370 389 390
75. Tofighi B., Lee J. D. Internet highs - seizures after consumption of synthetic cannabinoids purchased online. J Addict Med: 2012; 6 240 241
76. Lapoint J., James L. P., Moran C. L. et al. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila): 2011; 49 760 764
77. Seely K. A., Lapoint J., Moran J. H. et al. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry: 2012; 39 234 243
78. APA (American Psychiatric Association) Diagnostic And Statistical Manual Of Mental Disorders, Fifth Edition (DSM-5TM). Cannabis Withdrawal (292.0/F12.88). Washington, DC APA: 2013; 517 519
79. Alhadi S., Tiwari A., Vohra R. et al. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol: 2013; 9 199 206
80. Swift W., Wong A., Li K. M. et al. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One: 2013; 8 e70052
81. Nutt D. J., King L. A., Phillips L. D. Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet: 2010; 376 1558 1565
82. van Amsterdam J., Opperhuizen A., Koeter M. et al. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res: 2010; 16 202 207
83. Griffiths R. R., Johnson M. W. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry: 2005; 66 09 31 41
84. Halpin L. E., Collins S. A., Yamamoto B. K. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci: 2014; 97 37 44
85. Miotto K., Striebel J., Cho A. K. et al. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend: 2013; 132 1 12
86. Musselman M. E., Hampton J. P. Not for human consumption: a review of emerging designer drugs. Pharmacotherapy: 2014; 34 745 757
87. German C. L., Fleckenstein A. E., Hanson G. R. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci: 2014; 97 2 8
88. Paillet-Loilier M., Cesbron A., Le Boisselier R. et al. Emerging drugs of abuse: current perspectives on substituted cathinones. Subst Abuse Rehabil: 2014; 5 37 52
89. Hawley L. A., Auten J. D., Matteucci M. J. et al. Cardiac complications of adult methamphetamine exposures. J Emerg Med: 2013; 45 821 827
90. Panenka W. J., Procyshyn R. M., Lecomte T. et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend: 2013; 129 167 179
91. Carvalho M., Carmo H., Costa V. M. et al. Toxicity of amphetamines: an update. Arch Toxicol: 2012; 86 1167 1231
92. Cottencin O., Rolland B., Karila L. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr Pharm Des: 2014; 20 4106 4111
93. McNabb C. B., Russell B. R., Caprioli D. et al. Single chemical entity legal highs: assessing the risk for long term harm. Curr Drug Abuse Rev: 2012; 5 304 319
94. Liechti M. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly: 2015; 145 w14043
95. Bonnet U. Einschätzung des Abhängigkeitsrisikos von Propofol. Fortschr Neurol Psychiatr: 2011; 79 442 452
96. Brennan R., Van Hout M. C. Gamma-Hydroxybutyrate (GHB): A Scoping Review of Pharmacology, Toxicology, Motives for Use, and User Groups. J Psychoactive Drugs: 2014; 46 243 251
97. Brunt T. M., van Amsterdam J. G., van den Brink W. GHB, GBL and 1,4-BD addiction. Curr Pharm Des: 2014; 20 4076 4085
98. Corazza O., Assi S., Schifano F. From Special K to Special M: the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther: 2013; 19 454 460
99. Kalsi S. S., Wood D. M., Dargan P. I. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J: 2011; 4 7107
100. Bonnet U., Scherbaum N. Cannabisbezogene Störungen. Teil I: Pharmakologie, Epidemiologie und Therapieverfahren. Fortschr Neurol Psychiat: 2010; 78 297 305
101. Bonnet U., Scherbaum N. Cannabisbezogene Störungen. Teil II: Psychiatrische und somatische Folgestörungen und Komorbiditäten. Fortschr Neurol Psychiat: 2010; 78 360 370
102. Brown S. D., Melton T. C. Trends in bioanalytical methods for the determination and quantification of club drugs: 2000-2010. Biomed Chromatogr: 2011; 25 300 321
103. Ernst L., Krüger K., Lindigkeit R. et al. Synthetic cannabinoids in spice-like herbal blends: first appearance of JWH-307 and recurrence of JWH-018 on the German market. Forensic Sci Int: 2012; 222 216 222
104. Info Curia Rechtsprechung des Gerichtshofs. Im Internet: http://curia.europa.eu/juris/document/document.jsf;jsessionid=9ea7d2dc30d6686695f92d2b4b5d94a6c225f2d2b8f0.e34KaxiLc3qMb40Rch0SaxuOa310?text=&docid=154827&pageIndex=0&doclang=de&mode=req&dir=&occ=first&part=1&cid=214760 Stand: 08.02.2015
105. Bonnet U., Specka M., Stratmann U. et al. Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: Cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum. Drug Alcohol Depend: 2014; 143 189 197
106. Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, December 2014. http://www.grassley.senate.gov/sites/default/files/news/upload/3-factor%20analysis%20AB-CHMINACA%20AB-PINACA%20THJ2201%2012172014.pdf Stand: 14.03.2015
107. Werse B., Morgenstern C. Der Trend geht zur Reinsubstanz - Entwicklungen im Konsum von "Legal highs/neuen psychoaktiven Substanzen (NPS) auf Basis zweier Online-Befragungen. Suchttherapie: 2015; 16 36 41